DE69730966D1 - Morphogenische behandlung des chronischen nierenversagens - Google Patents

Morphogenische behandlung des chronischen nierenversagens

Info

Publication number
DE69730966D1
DE69730966D1 DE69730966T DE69730966T DE69730966D1 DE 69730966 D1 DE69730966 D1 DE 69730966D1 DE 69730966 T DE69730966 T DE 69730966T DE 69730966 T DE69730966 T DE 69730966T DE 69730966 D1 DE69730966 D1 DE 69730966D1
Authority
DE
Germany
Prior art keywords
treatment
chronic kidney
kidney failure
risk
morphogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69730966T
Other languages
English (en)
Other versions
DE69730966T2 (de
Inventor
T Sampath
M Cohen
Slobodan Vukicevic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DE69730966D1 publication Critical patent/DE69730966D1/de
Publication of DE69730966T2 publication Critical patent/DE69730966T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69730966T 1996-05-06 1997-05-06 Morphogenische behandlung des chronischen nierenversagens Expired - Lifetime DE69730966T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
US643321 1996-05-06
PCT/US1997/007816 WO1997041881A1 (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Publications (2)

Publication Number Publication Date
DE69730966D1 true DE69730966D1 (de) 2004-11-04
DE69730966T2 DE69730966T2 (de) 2006-02-23

Family

ID=24580305

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69723845T Expired - Lifetime DE69723845T2 (de) 1996-05-06 1997-05-06 Therapien des chronischen nierenversagens
DE69730966T Expired - Lifetime DE69730966T2 (de) 1996-05-06 1997-05-06 Morphogenische behandlung des chronischen nierenversagens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69723845T Expired - Lifetime DE69723845T2 (de) 1996-05-06 1997-05-06 Therapien des chronischen nierenversagens

Country Status (11)

Country Link
US (5) US6498142B1 (de)
EP (2) EP0910400B1 (de)
JP (4) JP2000510835A (de)
AT (2) ATE245997T1 (de)
AU (2) AU2832297A (de)
CA (2) CA2254953C (de)
DE (2) DE69723845T2 (de)
DK (2) DK0910400T3 (de)
ES (2) ES2230604T3 (de)
PT (2) PT910400E (de)
WO (2) WO1997041880A1 (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU743510B2 (en) * 1997-05-05 2002-01-24 Stryker Corporation Therapies for acute renal failure
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease
EP0896825B1 (de) 1997-08-14 2002-07-17 Sulzer Innotec Ag Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
WO1999028341A2 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
WO2000006716A1 (en) * 1998-07-28 2000-02-10 The Johns Hopkins University School Of Medicine Growth differentiation factor-11
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
US6992066B2 (en) * 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
EP1214091B1 (de) * 1999-09-14 2006-05-10 Biogen Idec MA Inc. Therapien für chronische niereninsuffizienz unter verwendung von einem oder mehreren integrinantagonist(en)
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
WO2004019876A2 (en) * 2002-08-28 2004-03-11 Curis, Inc. Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
CA2558029C (en) 2004-03-30 2013-05-07 Ilypsa, Inc. Ion binding polymers and uses thereof
EP1730186A2 (de) * 2004-03-31 2006-12-13 Xencor, Inc. Bmp-7 varianten mit verbesserten eigenschaften
WO2006130690A2 (en) * 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
JP2009515529A (ja) * 2005-11-14 2009-04-16 メリアル リミテッド 腎不全のための遺伝子療法
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
WO2007087570A2 (en) 2006-01-24 2007-08-02 Northfield Laboratories, Inc. Polymerized hemoglobin media and its use in isolation and transplantation of islet cells
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
US20090197280A1 (en) * 2006-05-30 2009-08-06 Kristian Bangert Methods and Devices for Rapid Assessment of Severity of Injury
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
WO2008010556A1 (fr) * 2006-07-21 2008-01-24 Chugai Seiyaku Kabushiki Kaisha Médicament agissant contre une maladie rénale
CA2672560A1 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universitaet Heidelberg Methods for treating podocyte-related disorders
EP2148706A2 (de) * 2007-04-24 2010-02-03 Advanced Technologies and Regenerative Medicine, LLC Gentechnisch hergestelltes nierengewebe
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
US20110104133A1 (en) * 2008-05-06 2011-05-05 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2009157165A1 (ja) * 2008-06-24 2009-12-30 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
EP2324355B1 (de) * 2008-08-28 2014-01-22 Astute Medical, Inc. Verfahren und zusammensetzungen zur diagnose und prognose von nierenverletzungen und niereninsuffizienz
CN102187219B (zh) * 2008-08-29 2015-08-05 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CA2740923A1 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102246035B (zh) 2008-10-21 2014-10-22 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
WO2010054389A1 (en) 2008-11-10 2010-05-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2811036A3 (de) * 2008-11-22 2015-02-18 Astute Medical, Inc. Verfahren und Zusammensetzungen zur Diagnose und Prognose von Nierenläsion und Niereninsuffizienz
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN106546752A (zh) * 2009-02-06 2017-03-29 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后
EP2396025A2 (de) 2009-02-12 2011-12-21 Stryker Corporation Periphere verabreichung von proteinen einschliesslich mitglieder der tgf-beta-superfamilie zur systemischen behandlung von störungen und erkrankungen
CN102369017A (zh) * 2009-02-12 2012-03-07 史赛克公司 用于微创系统性递送包含TGF-β超家族成员的蛋白质的组合物和方法
US8828937B2 (en) * 2009-03-12 2014-09-09 Haase Investments Ug Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
KR20120061863A (ko) 2009-08-07 2012-06-13 아스튜트 메디컬 인코포레이티드 신장 손상 및 신부전증의 진단과 예후를 위한 방법 및 조성물
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
NZ628085A (en) 2009-11-07 2015-12-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20120123056A (ko) 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
CN102822197A (zh) 2009-12-22 2012-12-12 史赛克公司 具有降低的免疫原性的bmp-7变体
MX366653B (es) 2010-02-05 2019-07-17 Astute Medical Inc Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
WO2011162819A1 (en) 2010-06-23 2011-12-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011106746A1 (en) 2010-02-26 2011-09-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
NZ605698A (en) 2010-06-23 2015-03-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN105198981B (zh) 2010-08-20 2019-07-16 惠氏有限责任公司 经设计的成骨蛋白
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
ES2933570T3 (es) 2011-12-08 2023-02-10 Astute Medical Inc Métodos y composiciones para el diagnóstico y el pronóstico de una lesión renal y de una insuficiencia renal
AU2013329451B2 (en) 2012-10-08 2018-08-09 Vifor (International) Ltd. Potassium-binding agents for treating hypertension and hyperkalemia
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CN107976547B (zh) 2013-01-17 2020-08-25 阿斯图特医药公司 用于肾损伤和肾衰竭的诊断及预后的方法和组合物
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
WO2015069998A1 (en) * 2013-11-11 2015-05-14 General Electric Company Method for reducing error in rotor speed measurements
EP2944326B1 (de) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanin-cyclodextrin-konjugate und deren verwendung zur diagnose von nierenkrankheiten
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US11243217B2 (en) 2016-06-06 2022-02-08 Astute Medical, Inc. Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2
WO2018035377A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
CA2030518C (en) 1989-03-28 2000-03-21 Elizabeth A. Wang Osteoinductive compositions
ATE209251T1 (de) 1990-05-16 2001-12-15 Genetics Inst Knochen- und knorpel-bildung hervorrufende proteine
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
EP0533840B1 (de) * 1990-06-22 1996-12-11 E.I. Du Pont De Nemours And Company Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
AU660019B2 (en) 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
CA2116562C (en) 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
ATE197611T1 (de) 1991-08-30 2000-12-15 Creative Biomolecules Inc Screeningverfahren von morphogenischen proteinen
JP4235689B2 (ja) 1991-08-30 2009-03-11 ストライカー・コーポレーション 骨疾患を処置するための骨形成タンパク質
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
JP4344012B2 (ja) 1992-07-31 2009-10-14 ストライカー・コーポレーション 組織形成因子誘導による神経の再生と修復
KR950702627A (ko) 1992-07-31 1995-07-29 찰스 엠. 코헨 모르포겐 단백질의 가용성 복합체 및 그의 조성물(Morphogenic Protein Soluble Complex and Composition Thereof)
JPH07509720A (ja) 1992-07-31 1995-10-26 クリエイティブ　バイオモレキュルズ，インコーポレイテッド モルフォゲン強化栄養組成物
ATE162078T1 (de) 1992-09-16 1998-01-15 Creative Biomolecules Inc Morphogeninduzierte regenerierung der leber
WO1994010203A2 (en) 1992-11-03 1994-05-11 Creative Biomolecules, Inc. Op-3-induced morphogenesis
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
CA2157387C (en) 1993-03-04 1998-12-15 David C. Rueger Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
CA2176709A1 (en) * 1993-11-15 1995-05-26 Howard R. Higley Method of treating renal disease by administering igf-i and igfbp-3
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
ES2201287T5 (es) * 1996-03-22 2007-10-16 Curis, Inc. Metodo para mejorar la recuperacion funcional de la coordinacion motora, del habla o la percepcion sensorial tras una isquemia o trauma del sistema nervioso central.
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
CA2254953A1 (en) 1997-11-13
JP2009185076A (ja) 2009-08-20
EP0914146A1 (de) 1999-05-12
AU2832297A (en) 1997-11-26
ATE277629T1 (de) 2004-10-15
US8017580B2 (en) 2011-09-13
ES2203803T3 (es) 2004-04-16
JP2000510124A (ja) 2000-08-08
ES2230604T3 (es) 2005-05-01
PT914146E (pt) 2005-02-28
WO1997041880A1 (en) 1997-11-13
US6861404B1 (en) 2005-03-01
AU2933997A (en) 1997-11-26
ATE245997T1 (de) 2003-08-15
WO1997041881A1 (en) 1997-11-13
JP2000510835A (ja) 2000-08-22
CA2254954C (en) 2010-01-12
CA2254953C (en) 2006-09-26
JP4766722B2 (ja) 2011-09-07
US20050143304A1 (en) 2005-06-30
DE69723845D1 (de) 2003-09-04
JP2012229268A (ja) 2012-11-22
US8377878B2 (en) 2013-02-19
DE69730966T2 (de) 2006-02-23
JP5247593B2 (ja) 2013-07-24
PT910400E (pt) 2003-12-31
DK0910400T3 (da) 2003-11-24
DK0914146T3 (da) 2005-01-31
US7524817B2 (en) 2009-04-28
EP0910400A1 (de) 1999-04-28
US20100291170A1 (en) 2010-11-18
US6498142B1 (en) 2002-12-24
EP0910400B1 (de) 2003-07-30
US20120004171A1 (en) 2012-01-05
EP0914146B1 (de) 2004-09-29
CA2254954A1 (en) 1997-11-13
DE69723845T2 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
DE69730966D1 (de) Morphogenische behandlung des chronischen nierenversagens
ATE278414T1 (de) Therapien zur behandlung von akutem nierenversagen
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
ID18729A (id) Sistem penggantian gigi, komponen-komponen untuk sistem penggantian gigi, dan metoda untuk penggantian gigi tersebut
NO970536D0 (no) Behandlingssystem for avgitt blod med skrå reguleringsgrenseflate
DE69432582T2 (de) System zur Administration von Flüssigkeiten bei mehreren Patienten
DE69710095T2 (de) Pharmazeutische zubereitung zur behandlung von diabetes
MXPA02006679A (es) Composicion farmaceutica.
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
ATE226442T1 (de) Anti-chlamydia verfahren und mittel
BR9709900A (pt) Proteìnas de ligacão de proteìnas de prìons e usos das mesmas.
HK1055255A1 (en) Implant comprising immunologically isolated stromal cells and its use
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
ATE361756T1 (de) Insulinartiger-wachstumsfaktorbindungsprotein-4 protease
ATE302021T1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52
DE29716635U1 (de) Distraktionsvorrichtung zur Behandlung von Knochendefekten
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ATE222479T1 (de) Einheit zur knorpelreparatur
DK0495226T3 (da) Anvendelse af 3-aryl-5-alkylthio-4H-1,2,4-triazoler til behandling af hyperrefleksi som følge af spinaltrauma
DK1214091T3 (da) Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
FR2764389B1 (fr) Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee
ATE206930T1 (de) Verwendung von osteoblast-proliferationsfaktor
DK0834316T3 (da) Anvendelse af sulbutiamin til behandling af psykomotoriske eller psykointellektuelle problemer
DE69614577D1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
DE59609353D1 (de) Mittel zur subkutanen Verabreichung von Protein C

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: STRYKER CORP., KALAMAZOO, MICH., US